Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: A randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU).

Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: A randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU).

<h4>Background</h4>After admission to hospital, COVID-19 progresses in a substantial proportion of patients to critical disease that requires intensive care unit (ICU) admission.<h4>Methods</h4>In a pragmatic, non-blinded trial, 387 patients aged 40-90 years were randomised t...

詳細記述

書誌詳細
主要な著者: Raja Dhar, John Kirkpatrick, Laura Gilbert, Arjun Khanna, Mahavir Madhavdas Modi, Rakesh K Chawla, Sonia Dalal, Venkata Nagarjuna Maturu, Marcel Stern, Oliver T Keppler, Ratko Djukanovic, Stephan D Gadola
フォーマット: 論文
言語:English
出版事項: Public Library of Science (PLoS) 2023-01-01
シリーズ:PLoS ONE
オンライン･アクセス:https://doi.org/10.1371/journal.pone.0280745

インターネット

https://doi.org/10.1371/journal.pone.0280745

類似資料